Business Context and Reporting Period
This Form 8-K is filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc., as noted in the metadata request) for the reporting period ending September 15, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol QLGN. The filing reports the entry into a material definitive agreement regarding a secured promissory note.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific debt metrics related to a recent amendment:
- Revised Outstanding Principal Balance: $4,526,462.18
- Additional Advance Amount: $75,000
- Revised Maturity Date: August 21, 2026
- Interest Rate: Accrues at the rate set forth in the original Amended and Restated Note (specific rate not disclosed in this summary).
- Collateral Status: Obligations remain secured under the existing Security Agreement.
Material Changes Versus Prior Period
On September 15, 2025, the Company executed Amendment No. 1 to the Amended and Restated Secured Demand Promissory Note originally dated August 21, 2025, with Marizyme, Inc. The material changes include:
- Correction of the maturity date to August 21, 2026.
- Increase in the principal amount outstanding by $75,000.
- Reaffirmation of the security interest held by the lender.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The primary risk disclosed is the creation of a direct financial obligation and the increase in secured debt. The text notes that the description of the amendment is a draft summary and is qualified in its entirety by reference to Exhibit 10.2.
Investor Verification Checklist
- Verify the specific interest rate applicable to the $4,526,462.18 principal balance by reviewing Exhibit 10.2.
- Confirm the terms of the existing Security Agreement to understand the assets pledged as collateral.
- Review the original August 21, 2025, Promissory Note (Exhibit 10.1) to understand the full context of the debt structure.
- Check for any subsequent filings regarding the company's liquidity position given the increased debt load.